Skip to content
Stack & save: 10% off 3+ vials, 15% off 5+ · Free shipping over $250
Cart 0
Compound Files

Melanotan 1 Research Guide: NDP-alpha-MSH, Identity, and Evidence

Understand Hero MT-1, its connection to NDP-alpha-MSH research, distinctions from MT-II and approved preparations, and the documentation needed for laboratory work.

Hero Peptides Research TeamUpdated Nov 20265 min read

Quick facts

Catalog name MT-1 Melanotan 1
Related literature terminology NDP-alpha-MSH, Melanotan-I
Structure class Alpha-MSH peptide analog
Exported size 10 mg
Identity boundary Confirm sequence and form; an approved formulation is a separate product
Hero product MT-1 Melanotan 1

Melanotan 1 is a name associated with NDP-alpha-MSH, an engineered analog of alpha-melanocyte-stimulating hormone. Its research history illustrates how a small number of structural substitutions can change a peptide’s experimental behavior. The name still needs an exact material specification when used in a laboratory record.

Hero’s export lists MT-1 Melanotan 1 with a 10 mg variant. This guide explains the related terminology, the original research background, and the important distinction between a research sample, another melanotropin analog, and an approved finished medicine.

MT-1 Melanotan 1. View catalog product

Origin story: the NDP-alpha-MSH connection

A 1980 paper described an alpha-MSH analog with norleucine and D-phenylalanine substitutions. The resulting NDP-alpha-MSH research is central to the historical background of the Melanotan-I name (Sawyer et al., 1980).

A substitution changes the structure being investigated. A change in activity should therefore be described using the specific analog and assay, rather than assigned to every peptide in the same family. The parent hormone and its engineered analogs remain distinct materials.

The terms NDP-alpha-MSH and Melanotan-I help locate relevant literature. For Hero’s material, verify the exact sequence, terminal chemistry, and stated form against the lot documentation. The export’s product name alone does not independently establish every structural detail.

How Melanotan 1 is studied

Melanocortin experiments can investigate receptor binding, intracellular signaling, enzyme activity, or later cellular responses. Each endpoint needs its own model and controls. A response measured in one system does not automatically describe the same process in another.

A later primary study examined NDP-alpha-MSH in the Cloudman S91 melanoma cell line and measured tyrosinase-related activity. This is a defined cellular model; it should not be rewritten as a clinical outcome for a separately supplied research product (Hadley et al., 1985).

That distinction is especially important for enzyme-related endpoints. More signal might reflect a change in enzyme activity, cell number, or another feature of the assay. The method and controls help determine which explanation is supported.

The Melanotan 2 guide covers a different cyclic analog. The shared name reflects related research history, while the structures and evidence must still be evaluated individually.

Key sources: discovery, cell research, and authorization

Source Subject What it supports What it does not establish
Sawyer et al., 1980 An engineered alpha-MSH analog Historical structure and biological-characterization context Identity or potency of every modern supplier lot
Hadley et al., 1985 Cloudman S91 cell experiments Results for a specified cell model A human outcome for Hero MT-1
FDA Scenesse record A specified afamelanotide medicine Approval for its stated indication Approval or interchangeability of a research vial

The FDA record identifies Scenesse, containing afamelanotide, as approved in 2019 for a specific erythropoietic protoporphyria indication. That authorization concerns the named medicine and its formulation. It does not extend to Hero’s MT-1 catalog entry (FDA, 2019).

A chemical relationship can explain why two names appear in the same search results. It does not establish that two preparations share manufacturing controls, analytical specifications, delivery characteristics, or approved uses.

When building an evidence summary, record both the molecule and the finished preparation where relevant. This prevents a correct statement about an authorized medicine from becoming a misleading statement about a separate laboratory material.

Weak spots: similarity does not replace characterization

As of November 17, 2026, this guide does not establish an approved clinical use for Hero MT-1. It also does not provide tanning instructions, a sunlight-exposure method, or a claim of protection from ultraviolet exposure.

A cellular study involving a melanoma-derived line should retain that model description. It is not evidence that a research vial prevents or treats cancer. Historical research aims and measured experimental findings must be distinguished.

Exact compound identity is another boundary. Sequence, stereochemistry, terminal modifications, and chemical form can matter to the method. A matching label or approximate molecular mass cannot independently establish every property an experiment may require.

Likewise, chromatographic purity is not a functional assay. If a study requires a defined response at a receptor or cellular endpoint, that response should be characterized with suitable standards and controls rather than assumed from a supplier percentage.

Handling Melanotan 1 in the lab

The exported 10 mg option describes nominal material mass. Consult the actual material specification and assay requirements before selecting a solvent or preparation condition. A finished-medicine label is not a laboratory preparation instruction for a separate sample.

For arithmetic only, nominal 10 mg at a final solution volume of 2 mL gives 5 mg/mL. At a final volume of 5 mL in a suitable vessel, it gives 2 mg/mL. These examples do not establish solubility or a biological test concentration.

For a later dilution, retain stock concentration, transferred volume, and final volume. Keep mass-based and molar comparisons separate. If molecular weight is needed, confirm the appropriate basis for the actual documented form.

The calculator and conversion guide help check arithmetic. The COA guide explains how to assess the complementary identity, purity, and content information.

Keep product ID, lot number, preparation date, solvent, and dilution history together. If the supplied documentation does not answer a property essential to the experiment, preserve that uncertainty rather than importing a number from a different material or supplier.

Melanotan 1 FAQ

Is Melanotan 1 another name for Melanotan 2?

No. They are distinct analogs. The number is part of the name, not a ranking or a statement of interchangeable strength.

Why do afamelanotide and Scenesse appear in related searches?

They are connected to the same molecular research history, but Scenesse is a specified finished medicine. That does not establish equivalence for a research vial.

Does a cell-study result predict a clinical outcome?

No. The result concerns the tested system and conditions. A clinical claim requires evidence addressing that clinical question.

What is Hero MT-1?

It is the MT-1 Melanotan 1 product in Hero’s supplied export, listed with a 10 mg variant. Confirm exact material identity and lot properties in its documentation.

MT-1 Melanotan 1. View catalog product

References

  1. Sawyer TK, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77(10):5754-5758. Source.
  2. Hadley ME, et al. [Nle4, D-Phe7]-alpha-MSH: a superpotent melanotropin that “irreversibly” activates melanoma tyrosinase. Endocr Res. 1985;11(3-4):157-170. Source.
  3. U.S. Food and Drug Administration. Scenesse (afamelanotide), orphan-drug approval record. Approval October 8, 2019; checked November 17, 2026. Source.
For laboratory research use only. Not for human or veterinary use. This article is educational and is not medical advice.

Read next

Add 3 vials for 10% off
Build my stack